PER-040-02已完成未知
MULTICENTRIC, OPEN, RANDOMIZED, COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TELITROMYCIN 800 MG VIA ORAL ONCE A DAY FOR 5 DAYS VS. AMOXICILLINE / CLAVULIC ACID 500/125 MG VIA ORAL THREE TIMES A DAY FOR 10 DAYS IN THE TREATMENT OF ACUTE MAXILAR SYNTHETIS OR MAXILAR-ACUTE ETHIOIDAL IN ADULTS.
AVENTIS PHARMA S.A.,0 个研究点目标入组 0 人开始时间: 2004年5月29日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Be 18 years old and have a diagnosis of acute maxillary sinusitis or
- •acute maxillary-ethmoidal uncomplicated.
排除标准
- •Patients who have had at least 3 episodes of maxillary sinusitis
- •acute or maxilar-ethmoidal acute in the last 12 months.
研究者
相似试验
进行中（未招募）
1 期
ANTICIPUSC: Preoperative anticipation of respiratory risk according to ARISCAT scoring system and prophylactic post-operative non-invasive ventilation, comparing to standard post-operative care in patients at high-risk of respiratory complicationsEUCTR2017-001011-36-FRINSTITUT DE CANCEROLOGIE DE L'OUEST266
进行中（未招募）
不适用
An open, randomised, comparative, multicentre study of the immunogenicity and safety of concomitant versus separate administration of a combined measles, mumps, rubella and varicella live vaccine (ProQuad®) and a booster dose of Infanrix® hexa in healthy children 12 to 23 months of age.EUCTR2006-004129-27-DESanofi Pasteur MSD960
进行中（未招募）
不适用
An open, randomised, comparative, multicentre study of the immunogenicity and safety of M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX® when administered concomitantly by intramuscular (IM) route or subcutaneous (SC) route at two separate injection sites in healthy subjects 12 to 18 months of age - MMR rHA + VARIVAX IM or SC in 12-18 month-old healthy subjectsot applicable - Healthy subjectsEUCTR2004-002586-21-DEAventis Pasteur MSD SNC700
尚未招募
不适用
Study of efficacy and safety of FormairCTRI/2017/01/007711Rus Biopharm150
进行中（未招募）
不适用
Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of Concomitant versus Separate administration of a combined measles, mumps, rubella and varicella live vaccine ProQuad and a Booster dose of Infanrix hexa in Healthy Children 12 to 23 months of age - X06-MMRV-302EUCTR2006-004129-27-ITCASA MADRE960